
Chief Marketing Officer departs Lazar
It is with mixed emotions that I announce the departure of Kate (Kathryn) Ross, Chief Marketing Officer at Lazar Pharmaceuticals since the company was founded in 2001.
Ross and the Lazar Pharmaceuticals Board of Directors came to a mutual agreement last evening that effective immediately they would part ways. I am not at liberty at this time to discuss the circumstances surrounding Ross’ departure, or comment on rumors that she leaked proprietary information related to the recent disappearances of two individuals involved in Lazar’s clinical trials.

Second disappearance an “unfortunate coincidence”
Authorities are investigating the disappearance of a second individual who was who was enrolled in one of Lazar’s clinical trials. George Lazar, President and CEO of Lazar Pharmaceuticals, calls this second disappearance “an unfortunate coincidence” and reiterates that as of this time, “there have been no charges filed and no accusations made regarding any criminal or improper activity on behalf of Lazar Pharmaceuticals.”

Marketing’s first magic numbers
To introduce you to the new Lazar Pharmaceuticals website, our Marketing Department has issued a series of “magic numbers”. The first visitor to decode the magic numbers listed below will receive a free Lazar Pharma branded polo shirt and golf cap. Good luck!

Addressing shareholder concerns
Given yesterday’s news about a government investigation that interviewed several Lazar Pharmaceutical employees, combined with the recent volatility in the stock market, I would like to address the concerns I’ve been hearing from our shareholders.
First off, the facts about the government investigation that was revealed on CNBC, CNN and other television news channels yesterday. This is NOT an investigation of Lazar Pharmaceuticals or any of our corporate activities. Rather, the Naval Criminal Investigative Service (NCIS) has questioned several Lazar employees in connection with the disappearance of a US Navy midshipman who was enrolled in one of Lazar’s clinical trials. Read more